Webpage for Tasigna With Facebook Link Is Misleading, FDA Says in ‘Untitled’ Letter

The Food and Drug Administration has told Novartis Pharmaceuticals Corp. that a webpage for Tasigna (nilotinib) containing a Facebook link is misleading because it fails to communicate any risk information associated with the use of the leukemia drug, according to an “untitled” letter posted Aug. 4 on FDA’s website.

The Tasigna website contains a “Facebook Share” social media widget that generates information on Tasigna created by Novartis that can be shared with Facebook users, FDA said. The shared content is misleading because it makes representations about the efficacy of Tasigna but fails to communicate any risk information. Additionally, the shared ...